Abstract:Background: The coronavirus disease-2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has urgently necessitated effective therapeutic solutions, with a focus on rapidly identifying and classifying potential small-molecule drugs. Given traditional methods' labor-intensive and time-consuming nature, deep learning has emerged as an essential tool for efficiently processing and extracting insights from complex biological data.Aims: This study aims to utilize deep learning techniques, particularly deep neural networks (DNN) enhanced with the synthetic minority oversampling technique (SMOTE), to enhance the classification of binding activities in anti-SARS-CoV-2 molecules across various bioassays.Methods: We used 11 bioassay datasets covering various SARS-CoV-2 interactions and inhibitory mechanisms. These assays ranged from spike-ACE2 protein-protein interaction to ACE2 enzymatic activity and 3CL enzymatic activity. To address the prevalent class imbalance in these datasets, the SMOTE technique was employed to generate new samples for the minority class. In our model-building approach, we divided the dataset into 80% training and 20% test sets, reserving 10% of the training set for validation. Our approach involved employing a DNN that integrates ReLU and sigmoid activation functions, incorporates batch normalization, and uses Adam optimization. The hyperparameters and architecture of the DNN were optimized through various tests on layers, minibatch sizes, epoch sizes, and learning rates. A 40% dropout rate was incorporated to mitigate overfitting. For model evaluation, we computed performance metrics, such as balanced accuracy (BACC), precision, recall, F1 score, Matthews' correlation coefficient (MCC), and area under the curve (AUC).Results: The performance of the DNN across 11 bioassay test sets revealed varying outcomes, significantly influenced by the ratios of active-to-inactive compounds. Assays, such as AlphaLISA and CoV-PPE, demonstrated robust performance across various metrics, including BACC, precision, recall, and AUC, when configured with more balanced ratios (1:3 and 1:1, respectively). This suggests the effective identification of active compounds in both cases. In contrast, assays with higher imbalance ratios, such as 3CL (1:38) and cytopathic effect (1:15), demonstrated higher recall but lower precision, highlighting challenges in accurately identifying active compounds among numerous inactive compounds. However, even in these challenging settings, the model achieved favorable BACC and recall scores. Overall, the DNN model generally performed well, as indicated by the BACC, MCC, and AUC values, especially when considering the degree of dataset imbalance in each assay.Conclusion: This study demonstrates the significant impact of deep learning, particularly DNN models enhanced with SMOTE, in improving the identification of active compounds in bioassay datasets for COVID-19 drug discovery, outperforming traditional machine learning models. Furthermore, this study highlights the efficacy of advanced computational techniques in addressing high-throughput screening data imbalances.

Imputation of Assay Bioactivity Data Using Deep Learning

Practical Applications of Deep Learning To Impute Heterogeneous Drug Discovery Data

Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set

Deep-learning: investigating deep neural networks hyper-parameters and comparison of performance to shallow methods for modeling bioactivity data

Embracing assay heterogeneity with neural processes for markedly improved bioactivity predictions

A Novel Deep Neural Network Technique for Drug–Target Interaction

Binding Activity Classification of Anti-SARS-CoV-2 Molecules using Deep Learning across Multiple Assays

Applications of Deep-Learning in Exploiting Large-Scale and Heterogeneous Compound Data in Industrial Pharmaceutical Research

The rise of deep learning and transformations in bioactivity prediction power of molecular modeling tools

Prediction of chemical compounds properties using a deep learning model

Data Integration Using Advances in Machine Learning in Drug Discovery and Molecular Biology

Enhancing Drug-Target Binding Affinity Prediction through Deep Learning and Protein Secondary Structure Integration

A deep learning method for drug-target affinity prediction based on sequence interaction information mining

519. DeepLPI: A Novel Drug Repurposing Model based on Ligand-Protein Interaction Using Deep Learning

Development and evaluation of a deep learning model for protein-ligand binding affinity prediction

Applications of Deep Learning in Molecule Generation and Molecular Property Prediction

Improved Prediction of Aqueous Solubility of Novel Compounds by Going Deeper With Deep Learning

Unleashing high content screening in hit detection - Benchmarking AI workflows including novelty detection

DeepAmes: A deep learning-powered Ames test predictive model with potential for regulatory application

Advancing Bioactivity Prediction through Molecular Docking and Self-Attention

Prediction of PLK1 PBD activity based on deep learning